John Hood
Directeur Général chez Actavalon, Inc.
Profil
John Hood is the founder of Biosplice Therapeutics, Inc. (founded in 2008) and Impact Biomedicines, Inc. (founded in 2016).
He held the title of Chief Scientific Officer at Biosplice Therapeutics, Inc. and Chief Executive Officer at Impact Biomedicines, Inc. Dr. Hood is also the founder of Endeavor BioMedicines, Inc. Dr. Hood's current job(s) include being the Chief Executive Officer & Director at Actavalon, Inc. since 2018 and the Director at Nine Square Therapeutics, Inc. since 2022.
Dr. Hood's education history includes undergraduate and doctorate degrees from Texas A&M University.
Postes actifs de John Hood
Sociétés | Poste | Début |
---|---|---|
Actavalon, Inc.
Actavalon, Inc. Pharmaceuticals: MajorHealth Technology Actavalon, Inc. operates as a preclinical stage pharmaceutical company. It focuses on the development of a single, broad spectrum, drug with the potential to target and eradicate human cancer cells of all types such as breast, lung, pancreatic and colon cancer among others. The company was founded by Ned Israelsen and Wesley G. Hatfield and is headquartered in San Diego, CA. | Directeur Général | - |
Endeavor BioMedicines, Inc
Endeavor BioMedicines, Inc Miscellaneous Commercial ServicesCommercial Services Endeavor BioMedicines, Inc is a clinical stage company located in Solana Beach, CA, that develops novel therapies for fibrosis and oncology. The company's lead program, env-101, is a hedgehog signalling inhibitor currently in phase 2 studies treating IPF, a progressive interstitial lung disease that causes inflammation and scarring in the lung. The company's second program is a HER3-targeted ADC that will begin clinical development in 2024 for the treatment of multiple solid tumors. The company's mission is to develop transformative medicines by targeting the underlying genetic and cellular causes of disease with best in class agents. Endeavor is partnered with XCures and is currently looking at the LOF mutation. Regardless of eligibility for the Endeavor trial, XCures will still send a list of other treatment options that could work for the cancer mutation. The company was founded by Miguel A. de los Ríos and John Hood, with John Hood serving as the CEO since incorporation. | Directeur Général | - |
Nine Square Therapeutics, Inc.
Nine Square Therapeutics, Inc. BiotechnologyHealth Technology Nine Square Therapeutics, Inc. provides biotechnology services. The company was founded in 2020 and is headquartered in New York, NY. | Directeur/Membre du Conseil | 13/09/2022 |
Anciens postes connus de John Hood
Sociétés | Poste | Fin |
---|---|---|
Impact Biomedicines, Inc.
Impact Biomedicines, Inc. Medical SpecialtiesHealth Technology Impact Biomedicines, Inc. engages in the development of cancer treatments. It engages in the development of fedratinib, a potent and selective oral molecule JAK2 kinase inhibitor for the treatment of myelofibrosis and polycythemia vera. The company was founded by John Hood, Catriona Jamieson and Raghu Saripalli in 2016 and is headquartered in San Diego, CA. | Directeur Général | 01/01/2018 |
Biosplice Therapeutics, Inc.
Biosplice Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Biosplice Therapeutics, Inc. provides medical research and development for tissue-level regeneration. It develops therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. The company was founded by Osman Kibar and John Hood in 2008 and is headquartered in San Diego, CA. | Fondateur | - |
Formation de John Hood
Texas A&M University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 5 |
---|---|
Biosplice Therapeutics, Inc.
Biosplice Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Biosplice Therapeutics, Inc. provides medical research and development for tissue-level regeneration. It develops therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. The company was founded by Osman Kibar and John Hood in 2008 and is headquartered in San Diego, CA. | Commercial Services |
Impact Biomedicines, Inc.
Impact Biomedicines, Inc. Medical SpecialtiesHealth Technology Impact Biomedicines, Inc. engages in the development of cancer treatments. It engages in the development of fedratinib, a potent and selective oral molecule JAK2 kinase inhibitor for the treatment of myelofibrosis and polycythemia vera. The company was founded by John Hood, Catriona Jamieson and Raghu Saripalli in 2016 and is headquartered in San Diego, CA. | Health Technology |
Actavalon, Inc.
Actavalon, Inc. Pharmaceuticals: MajorHealth Technology Actavalon, Inc. operates as a preclinical stage pharmaceutical company. It focuses on the development of a single, broad spectrum, drug with the potential to target and eradicate human cancer cells of all types such as breast, lung, pancreatic and colon cancer among others. The company was founded by Ned Israelsen and Wesley G. Hatfield and is headquartered in San Diego, CA. | Health Technology |
Endeavor BioMedicines, Inc
Endeavor BioMedicines, Inc Miscellaneous Commercial ServicesCommercial Services Endeavor BioMedicines, Inc is a clinical stage company located in Solana Beach, CA, that develops novel therapies for fibrosis and oncology. The company's lead program, env-101, is a hedgehog signalling inhibitor currently in phase 2 studies treating IPF, a progressive interstitial lung disease that causes inflammation and scarring in the lung. The company's second program is a HER3-targeted ADC that will begin clinical development in 2024 for the treatment of multiple solid tumors. The company's mission is to develop transformative medicines by targeting the underlying genetic and cellular causes of disease with best in class agents. Endeavor is partnered with XCures and is currently looking at the LOF mutation. Regardless of eligibility for the Endeavor trial, XCures will still send a list of other treatment options that could work for the cancer mutation. The company was founded by Miguel A. de los Ríos and John Hood, with John Hood serving as the CEO since incorporation. | Commercial Services |
Nine Square Therapeutics, Inc.
Nine Square Therapeutics, Inc. BiotechnologyHealth Technology Nine Square Therapeutics, Inc. provides biotechnology services. The company was founded in 2020 and is headquartered in New York, NY. | Health Technology |